Hemoglobin A1c Has Suboptimal Performance to Diagnose and Monitor Diabetes Mellitus in Patients with Cirrhosis (original) (raw)

Abstract

Background

Glycated hemoglobin A1c (HbA1c) is routinely used to diagnose and monitor type 2 diabetes mellitus (T2DM) in cirrhotic patients. Remarkably, HbA1c may be falsely low in such patients.

Aims

We assessed the diagnostic and monitoring yield of HbA1c in cirrhotic patients with T2DM (DM-Cirr) and without T2DM (NoDM-Cirr).

Methods

We conducted a composite study allocating 21 NoDM-Cirr into a cross-sectional module and 16 DM-Cirr plus 13 controls with T2DM only (DM-NoCirr) into a prospective cohort. Oral glucose tolerance test (OGTT) was performed in NoDM-Cirr. DM-Cirr and DM-NoCirr were matched by sex, age, BMI, and T2DM treatment and studied with continuous glucose monitoring (CGM). Percent deviations from target, low/high blood glucose indexes (LBGI/HBGI) were calculated from CGM, as well as the average daily risk range (ADRR) as a marker of glucose variability.

Results

Overall, HbA1c and OGTT diagnostic yield agreed in 12 patients (57%, ρ = 0.45, p < 0.03). CGM captured 3463 glucose determinations in DM-Cirr and 4273 in DM-NoCirr (_p_ = 0.42). Regression analysis showed an inferior association between HbA1c and CGM in DM-Cirr (_R_2 = 0.52), when compared to DM-NoCirr (_R_2 = 0.94), and fructosamine did not improve association for DM-Cirr (_R_2 = 0.31). Interestingly, cirrhosis and Child–Turcotte–Pugh class accounted for HbA1c variance (_p_ < 0.05). Patients in DM-Cirr were less frequently within target glucose (70–180 mg/dL), but at higher risk for hyperglycemia (HBGI > 9) when compared to DM-NoCirr, and they also showed higher glucose variability (ADRR 13.9 ± 2.5 vs. 8.9 ± 1.8, respectively, p = 0.03).

Conclusion

HbA1c inaccurately represents chronic glycemia in patients with cirrhosis, likely in relation to increased glucose variability.

Access this article

Log in via an institution

Subscribe and save

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Abbreviations

T2DM:

Type 2 diabetes mellitus

NoDM-Cirr:

Cirrhosis but no T2DM

DM-Cirr:

Cirrhosis and T2DM

DM-NoCirr:

T2DM without cirrhosis

OGTT:

Oral glucose tolerance test

HbA1c:

Glycated hemoglobin A1c

CGM:

Continuous glucose monitors

ALT:

Alanine aminotransferase

AST:

Aspartate aminotransferase

TIPS:

Transjugular intrahepatic portosystemic shunt

BMI:

Body mass index

INR:

International normalized ratio

NGSP:

National Glycohemoglobin Standardization Program

NPO:

Nothing by mouth

SD:

Standard deviation

IQR:

Interquartile range

MELD:

Model for end-stage liver disease

MELD-Na:

MELD-sodium

LBGI:

Low blood glucose index

HBGI:

High blood glucose index

ADRR:

Average daily risk range

HOMA-IR:

Homeostatic model assessment for insulin resistance

95% CI:

Confidence interval

References

  1. Hashiba M, Ono M, Hyogo H, et al. Glycemic variability is an independent predictive factor for development of hepatic fibrosis in nonalcoholic fatty liver disease. PloS ONE. 2013;8:e76161.
    Article CAS Google Scholar
  2. Schiaffini R, Liccardo D, Alisi A, et al. Early glucose derangement detected by continuous glucose monitoring and progression of liver fibrosis in nonalcoholic fatty liver disease: an independent predictive factor? Horm Res Paediatr. 2016;85:29–34.
    Article CAS Google Scholar
  3. Elkrief L, Rautou PE, Sarin S, Valla D, Paradis V, Moreau R. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver Int. 2016;36:936–948.
    Article CAS Google Scholar
  4. Huang JF, Yu ML, Dai CY, et al. Reappraisal of the characteristics of glucose abnormalities in patients with chronic hepatitis C infection. Am J Gastroenterol. 2008;103:1933–1940.
    Article CAS Google Scholar
  5. Garvey P, Murphy N, Flanagan P, et al. Disease outcomes in a cohort of women in Ireland infected by hepatitis C-contaminated anti-D immunoglobulin during 1970s. J Hepatol. 2017;67:1140–1147.
    Article Google Scholar
  6. Jepsen P, Watson H, Andersen PK, Vilstrup H. Diabetes as a risk factor for hepatic encephalopathy in cirrhosis patients. J Hepatol. 2015;63:1133–1138.
    Article Google Scholar
  7. Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol. 2013;108:881–891.
    Article CAS Google Scholar
  8. Piano S, Morando F, Carretta G, et al. Predictors of early readmission in patients with cirrhosis after the resolution of bacterial infections. Am J Gastroenterol. 2017;112:1575–1583.
    Article Google Scholar
  9. Gonzalez HC, Duarte-Rojo A. Virologic cure of hepatitis C: impact on hepatic fibrosis and patient outcomes. Curr Gastroenterol Rep. 2016;18:32.
    Article Google Scholar
  10. Nathan DM, Turgeon H, Regan S. Relationship between glycated haemoglobin levels and mean glucose levels over time. Diabetologia. 2007;50:2239–2244.
    Article CAS Google Scholar
  11. D’Amico G, Pasta L, Morabito A, et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther. 2014;39:1180–1193.
    Article Google Scholar
  12. American Diabetes A. 2. Classification and diagnosis of diabetes. Diabetes Care. 2017;40:S11–S24.
    Article Google Scholar
  13. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27:1487–1495.
    Article Google Scholar
  14. Altman DG, Gardner MJ. Calculating confidence intervals for regression and correlation. Br Med J (Clin Res Ed). 1988;296:1238–1242.
    Article CAS Google Scholar
  15. Clarke W, Kovatchev B. Statistical tools to analyze continuous glucose monitor data. Diabetes Technol Ther. 2009;11:S45–S54.
    Article CAS Google Scholar
  16. Monaghan M, Younge TB, McCarter R, Cogen FR, Streisand R. Average daily risk range (ADRR) in young children with type 1 diabetes. J Diabetes Sci Technol. 2014;8:70–73.
    Article Google Scholar
  17. Roglic G, World Health Organization. Global Report on Diabetes. Geneva, Switzerland: World Health Organization; 2016:86.
    Google Scholar
  18. Mokdad AA, Lopez AD, Shahraz S, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med. 2014;12:145.
    Article Google Scholar
  19. Pattullo V, Duarte-Rojo A, Soliman W, et al. A 24-week dietary and physical activity lifestyle intervention reduces hepatic insulin resistance in the obese with chronic hepatitis C. Liver Int. 2013;33:410–419.
    Article Google Scholar
  20. Haraguchi M, Miyaaki H, Ichikawa T, et al. Glucose fluctuations reduce quality of sleep and of life in patients with liver cirrhosis. Hepatol Int. 2017;11:125–131.
    Article Google Scholar
  21. Ochi T, Kawaguchi T, Nakahara T, et al. Differences in characteristics of glucose intolerance between patients with NAFLD and chronic hepatitis C as determined by CGMS. Sci Rep. 2017;7:10146.
    Article Google Scholar
  22. Kishimoto M, Noda M. Verification of glycemic profiles using continuous glucose monitoring: cases with steroid use, liver cirrhosis, enteral nutrition, or late dumping syndrome. J Med Invest. 2015;62:1–10.
    Article Google Scholar
  23. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008;31:1473–1478.
    Article CAS Google Scholar
  24. Lahousen T, Hegenbarth K, Ille R, et al. Determination of glycated hemoglobin in patients with advanced liver disease. World J Gastroenterol. 2004;10:2284–2286.
    Article CAS Google Scholar
  25. Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. New Engl J Med. 2008;359:1018–1026.
    Article CAS Google Scholar
  26. Gallagher EJ, Le Roith D, Bloomgarden Z. Review of hemoglobin A(1c) in the management of diabetes. J Diabetes. 2009;1:9–17.
    Article CAS Google Scholar
  27. Sartore G, Chilelli NC, Burlina S, Lapolla A. Association between glucose variability as assessed by continuous glucose monitoring (CGM) and diabetic retinopathy in type 1 and type 2 diabetes. Acta Diabetol. 2013;50:437–442.
    Article CAS Google Scholar
  28. Shah AG, Lydecker A, Murray K, et al. Use of the FIB4 index for non-invasive evaluation of fibrosis in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7:1104–1112.
    Article CAS Google Scholar

Download references

Acknowledgment

We would like to thank Dr. Peter Goulden from the Division of Endocrinology and Metabolism for his kind advice and support during conception and implementation of the study.

Funding

This study was funded in full by a Diabetes Research Grant from the Sturgis Foundation and the University of Arkansas for Medical Sciences College of Medicine Clinician Scientist Program.

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Naga S. Addepally, Roberto Martinez-Macias, Mauricio Garcia-Saenz-de-Sicilia & Andres Duarte-Rojo
  2. Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Nayana George
  3. Division of Gastroenterology and Hepatology, Stanford University, Palo Alto, CA, USA
    W. Ray Kim

Authors

  1. Naga S. Addepally
  2. Nayana George
  3. Roberto Martinez-Macias
  4. Mauricio Garcia-Saenz-de-Sicilia
  5. W. Ray Kim
  6. Andres Duarte-Rojo

Corresponding author

Correspondence toAndres Duarte-Rojo.

Ethics declarations

Conflict of Interest

Authors have nothing to disclose

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of our Institutional Review Board (UAMS IRB) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

About this article

Cite this article

Addepally, N.S., George, N., Martinez-Macias, R. et al. Hemoglobin A1c Has Suboptimal Performance to Diagnose and Monitor Diabetes Mellitus in Patients with Cirrhosis.Dig Dis Sci 63, 3498–3508 (2018). https://doi.org/10.1007/s10620-018-5265-3

Download citation

Keywords

Profiles

  1. Roberto Martinez-Macias View author profile
  2. Andres Duarte-Rojo View author profile